Stereotaxis, Inc. (STXS)

ASE – Real Time Price. Currency in USD

1.92

+0.04 (2.13%)

At close: May 12, 2026, 4:00 PM EDT

1.85

-0.07 (-3.65%)

Pre-market: May 13, 2026, 4:02 AM EDT

13.05.2026

Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript

12.05.2026

Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates

Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.07 per share a year ago.

12.05.2026

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

ST. LOUIS, May 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the first quarter ended March 31, 2026.

23.04.2026

Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval

STXS stock gains after first U.S. MAGiC procedures, marking a key milestone in robotic cardiac care and boosting its growth outlook.

22.04.2026

Stereotaxis Announces First MAGiC Procedures in the United States

ST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the US have been successfully treated using MAGiC™.

21.04.2026

Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026

ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 first quarter on Tuesday, May 12, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments.

17.04.2026

STXS to Acquire Robocath to Lead in Endovascular Robotics Market

Stereotaxis expands in robotic surgery with Robocath acquisition, aiming to build a comprehensive endovascular platform and unlock growth opportunities.

Videos

No Data

There is no data to display

Stereotaxis Announces Definitive Agreement to Acquire Robocath

ST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has entered into a definitive agreement to acquire Robocath, a venture-backed innovator of robotic technologies for interventional cardiology and neurointerventions.

06.04.2026

Stereotaxis Announces FDA Clearance and Launch of Synchrony System

ST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration 510(k) clearance for the Synchrony™ system.

Stereotaxis, Inc. (STXS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Stereotaxis, Inc. (STXS)

Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript

Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval

Stereotaxis Announces First MAGiC Procedures in the United States

Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026

STXS to Acquire Robocath to Lead in Endovascular Robotics Market

Videos

No Data

Press releases

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

Stereotaxis Announces First MAGiC Procedures in the United States

Stereotaxis Announces Definitive Agreement to Acquire Robocath

Stereotaxis Announces FDA Clearance and Launch of Synchrony System

Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript

Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval

Stereotaxis Announces First MAGiC Procedures in the United States

Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026

STXS to Acquire Robocath to Lead in Endovascular Robotics Market

Videos

No Data

Press releases

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

Stereotaxis Announces First MAGiC Procedures in the United States

Stereotaxis Announces Definitive Agreement to Acquire Robocath

Stereotaxis Announces FDA Clearance and Launch of Synchrony System

Search stocks

Stereotaxis, Inc. (STXS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Stereotaxis, Inc. (STXS)

Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript

Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval

Stereotaxis Announces First MAGiC Procedures in the United States

Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026

STXS to Acquire Robocath to Lead in Endovascular Robotics Market

Videos

No Data

Press releases

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

Stereotaxis Announces First MAGiC Procedures in the United States

Stereotaxis Announces Definitive Agreement to Acquire Robocath

Stereotaxis Announces FDA Clearance and Launch of Synchrony System

Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript

Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval

Stereotaxis Announces First MAGiC Procedures in the United States

Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026

STXS to Acquire Robocath to Lead in Endovascular Robotics Market

Videos

No Data

Press releases

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

Stereotaxis Announces First MAGiC Procedures in the United States

Stereotaxis Announces Definitive Agreement to Acquire Robocath

Stereotaxis Announces FDA Clearance and Launch of Synchrony System